Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01836809 · ClinicalTrials.gov registry record · Phase 4
Nesiritide and Renal Function After the Total Artificial Heart
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT01836809 is a Phase 4 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 2 participants.
The verdict
NCT01836809, a Phase 4 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The prevalence of renal dysfunction after implantation of the artificial heart is high. The infusion of exogenous B-type natriuretic peptide (BNP) after implantation of the total artificial heart (TAH) improves renal function in a sustained manner. The renal protective and hormone-modulating effects of nesiritide may be enhanced with ventriculectomy compared to heart failure surgery that leaves the native myocardium intact. The goal of this project is to determine the renal protective effects of nesiritide after implantation of a mechanical device.
Interventions
- DRUG placebo
- DRUG nesiritide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01836809
The ClinicalTrials.gov registry entry for NCT01836809 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01836809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01836809 about?
NCT01836809 is a clinical study titled "Nesiritide and Renal Function After the Total Artificial Heart". The prevalence of renal dysfunction after implantation of the artificial heart is high. The infusion of exogenous B-type natriuretic peptide (BNP) after implantation of the total artificial heart (TAH) improves renal function in a sustained manner. The renal protective and hormone-modulating effects...
What is the current status of trial NCT01836809?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2013-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01836809?
The interventions under investigation include: placebo (DRUG), nesiritide (DRUG).
Who is sponsoring clinical trial NCT01836809?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.